LifeArc’s Post

and for the life sciences sector, that also requires synergy between economic and health policy.....

EFPIA supports the Council Conclusions' call for a future-proof #IndustrialPolicy strategy to be an integral part of the Commission’s agenda in the next mandate. In recent years, other regions of the world have become more #competitive and attractive for innovators. The medicine investment gap between the US and the EU has increased by 1000% over the past 20 years. To close the gap, we need to create conditions that foster and drive research and development in the EU. A European industrial policy strategy with #health and #LifeSciences at its heart is a key step towards a healthier, more competitive, and resilient Europe: https://lnkd.in/g_TGW6gy #WeWontRest

TOUGH ASK A client (who remains nameless for reasons of commercial confidentiality) requested me to war-game what tough questions potential external funders might ask. When investors or grant funding agencies want to know about potential #marketsize for a product or service which doesn’t yet exist, that’s an obvious question to ask, and a difficult one to answer. And it’s only a starting point. My response was to identify, categorise and review questions suggested by over a dozen sources, refine the questions they posed and then derive additional ones, specific to the new category and the unmet needs the #innovation could address. That in turn stimulated the client to develop questions of their own. At a later stage, the client engaged me to obtain answers through #secondaryresearch  No market or industry report will tell you how many “laboratories” there are in the UK because laboratory activities are undertaken by organisations in various different sectors, undertaking various different forms of research, for different purposes.  So, how many are there? Is there any way to come up with a reliable estimate? WHAT QUESTIONS DOES YOUR ORGANISATION NEED ANSWERING?

Despite a clear scientific and commercial imperative, a significant gap between patient and trial populations persists. We explain why diversity in #clinicaltrials matters to investors and explore our engagement with companies. https://bit.ly/3NUZp1c For professional investors in EMEA and APAC only.

Yesterday, DSIT Secretary Peter Kyle delivered an insightful speech at the Campaign for Science and Engineering Conference, where he reaffirmed the government’s commitment to R&D investment. For those who have missed the speech, here are a few key takeaways: - Continued long-term support for R&D funding to drive innovation. Emphasis on high-growth sectors like healthcare, clean energy, and AI. - Focus on equitable R&D impact across regions and communities. - Strengthening the UK’s global leadership in science and technology. Personally, it’s encouraging to see that, even with a change in leadership, support for innovation and technological advancements remains strong. But we’ll need to wait for the upcoming budget for more detailed plans. While this commitment is promising, I would also like to see more done to protect the integrity of this scheme. Currently, questionable claims for funding — often due to businesses receiving poor advice from lots of amateur practices are noticeable — these are making it harder for legitimate applicants, with HMRC also facing delays as a result. I am committed to see a clearer framework to ensure that genuine claims receive timely support. Feel free to connect with me to stay up to date on more recent developments in the sector of R&D Investments. #Research #Innovation #GovernmentInvestments #ResearchFunding #InnovationFunding #InnovationRelief #AI #Healthcare #CleanEnergy #DSIT #ResearchAndDevelopment

For the past year, SCI has been campaigning for a radical overhaul of the government's approach to industrial policy, as the only way to avoid the UK losing scientific businesses to its overseas rivals and maintain its position on the global stage. Last week, in a landmark assessment of the future of the UK's capital markets, Sir Nigel Wilson highlighted a fundamental problem with the UK's haphazard approach to industrial policy over the past decade, which has led to the loss of billions of pounds worth of investment and growth potential. His findings are backed up by SCI's own research which earlier this year found that, of the 9 UK life science companies to achieve unicorn status (worth over $1bn) in the last decade, only two actually listed in the UK. We are calling on the new government must act now to avoid this becoming a perennial problem. Read more about the report's findings here: https://okt.to/bftY6x

"I’m not sure we’re saving the lives of our grandchildren with what we do." Many thanks to Michiel Scheffer for speaking to me about the future of the EIC, the importance of public procurement, and how companies can make the most out of their EU funding. The article is part of our new Funding Newswire newsletter, which members of the Science|Business Network can sign up to for free. https://lnkd.in/eRvs-_WU

In a decade that will be crucial for the UK, how can we ensure that we make the most of our innovations? Check out the latest article in PA's series on the pressing questions facing the UK, written by my colleagues Laycha Hugoosgift and Shaun Delaney. Let's explore together how we can reap the full benefits of our innovations and drive progress for our country. #UKinnovations #UKprogress #bigquestions

Health care and life science companies choose carefully where to invest, and decisions are based on a number of factors. Availability of strong science, funding and venture capital; ease of carrying out clinical trials; good patient access and how countries value and reward innovation and critically, how stable and competitive a region’s intellectual property framework is.

In some cases, it is not direct support that is important, but the creation of an appropriate #innovation environment. In a highly functioning innovation environment, the #cooperation of different actors, the existence and possibility of different forms of collaboration, and the flow of knowledge and information represented by the different #stakeholders provide the right environment for the creation of high-quality services. This requires a holistic approach by research & development (R&D) and innovation policymakers.🎥https://lnkd.in/ddJQC5Bv